[go: up one dir, main page]

BG102355A - METHOD OF STIMULATION OF CELL MEDIUM IMMUNIORS BY DIRECTION OF A DEFINED GENETIC SEQUENCE - Google Patents

METHOD OF STIMULATION OF CELL MEDIUM IMMUNIORS BY DIRECTION OF A DEFINED GENETIC SEQUENCE

Info

Publication number
BG102355A
BG102355A BG102355A BG10235598A BG102355A BG 102355 A BG102355 A BG 102355A BG 102355 A BG102355 A BG 102355A BG 10235598 A BG10235598 A BG 10235598A BG 102355 A BG102355 A BG 102355A
Authority
BG
Bulgaria
Prior art keywords
antigene
immuniors
stimulation
genetic sequence
cell medium
Prior art date
Application number
BG102355A
Other languages
Bulgarian (bg)
Inventor
Louis FALO
Kenneth Rock
Original Assignee
University Of Pitisburgh Of The Commonwealth System Of Highe
Dana-Faber Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pitisburgh Of The Commonwealth System Of Highe, Dana-Faber Cancer Institute filed Critical University Of Pitisburgh Of The Commonwealth System Of Highe
Publication of BG102355A publication Critical patent/BG102355A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to different methods of geneticimmunization intended to form antigene-specific immunity in amammal host, including humans. The method includes the orientationof specific seminucleotides expressing antigene protein or proteinfragment in the cytoplasm of target mice of the host, beingantigenes which stimulates the production of antigene-specific(CTL) cytotoxic T-lymphocyte. This assists the destruction of theaffected cells, for example the neoplastic and the virallyinfested cells.47 claims
BG102355A 1995-09-28 1998-03-26 METHOD OF STIMULATION OF CELL MEDIUM IMMUNIORS BY DIRECTION OF A DEFINED GENETIC SEQUENCE BG102355A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53555695A 1995-09-28 1995-09-28
PCT/US1996/015728 WO1997011605A1 (en) 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization

Publications (1)

Publication Number Publication Date
BG102355A true BG102355A (en) 1999-04-30

Family

ID=24134735

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102355A BG102355A (en) 1995-09-28 1998-03-26 METHOD OF STIMULATION OF CELL MEDIUM IMMUNIORS BY DIRECTION OF A DEFINED GENETIC SEQUENCE

Country Status (15)

Country Link
EP (1) EP0863704A4 (en)
JP (1) JPH11512724A (en)
KR (1) KR19990063672A (en)
CN (1) CN1201369A (en)
AU (1) AU716497B2 (en)
BG (1) BG102355A (en)
CA (1) CA2233278A1 (en)
CZ (1) CZ92998A3 (en)
HU (1) HUP9802651A3 (en)
NO (1) NO981386L (en)
NZ (1) NZ319891A (en)
PL (1) PL325953A1 (en)
SK (1) SK40198A3 (en)
TR (1) TR199800573T2 (en)
WO (1) WO1997011605A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044446A1 (en) * 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
JP2002507392A (en) * 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド Optimization of immunomodulatory properties of gene vaccines
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2370646A1 (en) * 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization
JP4430868B2 (en) * 2001-03-30 2010-03-10 ジーエイチシー リサーチ ディベロップメント コーポレイション Monocyte specific particulate delivery vehicle
JP5033303B2 (en) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Polynucleotides encoding polypeptides with antigenic type C HIV, polypeptides and uses thereof
US11529414B2 (en) 2020-06-23 2022-12-20 Orbis Health Solutions, Llc Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Also Published As

Publication number Publication date
SK40198A3 (en) 1998-11-04
HUP9802651A3 (en) 2001-08-28
EP0863704A4 (en) 2003-09-10
JPH11512724A (en) 1999-11-02
TR199800573T2 (en) 1998-07-21
CA2233278A1 (en) 1997-04-03
CN1201369A (en) 1998-12-09
AU716497B2 (en) 2000-02-24
NO981386D0 (en) 1998-03-26
KR19990063672A (en) 1999-07-26
NO981386L (en) 1998-05-28
PL325953A1 (en) 1998-08-17
WO1997011605A1 (en) 1997-04-03
HUP9802651A2 (en) 1999-02-01
NZ319891A (en) 1999-01-28
CZ92998A3 (en) 1998-09-16
EP0863704A1 (en) 1998-09-16
AU7251596A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
FR19C1020I1 (en) NEW B7-4 MOLECULES AND THEIR USES
EP0088195A3 (en) Messenger rna, production and use thereof
DE69128893D1 (en) GENETIC MODIFICATION OF ENDOTHEL CELLS
PT871482E (en) Recombinant vesiculoviruses and their uses
NZ335945A (en) Presenilin proteins and genetic sequences that are related to Alzheimer's disease
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
MX9706050A (en) Bioactive fusion proteins and pre-existing tumor therapy.
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
DK0941318T5 (en) Dumbbell-shaped gene expression expression systems
FI883722A0 (en) ALPHA-ENZYME ENZYMKOMPOSITIONER OCH FOERFARANDEN FOER DERAS FRAMSTAELLNING OCH ANVAENDNING.
MX9800719A (en) Transport proteins and their uses.
NO961115D0 (en) Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
NO970740L (en) Glutamate receptor
MX9705039A (en) Programmed cell death genes and proteins.
MX9708791A (en) Ataxia-telangiectasia gene and its genomic organization.
BG102355A (en) METHOD OF STIMULATION OF CELL MEDIUM IMMUNIORS BY DIRECTION OF A DEFINED GENETIC SEQUENCE
AU4940096A (en) Host cell expressing reduced levels of a metalloprotease and methods using the host cell in protein production
IL127297A0 (en) Spruce budworm antifreeze proteins genes and methods of using same
AU8258591A (en) Human mk gene and protein sequence
AU1060397A (en) High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
ATE89317T1 (en) PROTEINS, EXPRESSION VECTORS CONTAINING DNA ENCODING FOR SUCH PROTEINS, AND CELLS CONTAINING SUCH EXPRESSION VECTORS.
UA43308C2 (en) Process for imparting plant resistance to sclerostinious
AU3107684A (en) Proteins, pharmaceutical compositions, genes, vectors, host organisms and processes for their production
DE59712554D1 (en) RECOMBINANT EXPRESSION OF S-LAYER PROTEINS
IT8119759A0 (en) HUMAN, DNA AND PLASMIDS WHICH PRODUCT POLYPEPTIDE CODE FOR THIS SEQUENCE, MICROBIOLOGICALLY WITH THE SEQUENCE MICROORGANISMS THAT CONTAIN INTERFERON AMINO ACIDS THIS GENETIC INFORMATION AND PROCESS FOR THEIR PREPARATION.